<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310606</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A00710-53</org_study_id>
    <nct_id>NCT03310606</nct_id>
  </id_info>
  <brief_title>Serum and Peritoneal Concentration in Antibiotics During the Surgical Management of Peritonitis</brief_title>
  <acronym>SPAC</acronym>
  <official_title>Serum and Peritoneal Concentration in Antibiotics During the Surgical Management of Peritonitis: SPAC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SPAC is a pilote monocentric prospective study about peritonitis and antibiotics
      pharmacokinetic and pharmacodynamic. The investigators will included 50 patients during 2
      years in the University Hospital of Nancy.

      The aim of this study is to determine if the beta-lactam dosages recommended by the
      guidelines for management of intra-abdominal infections (published by the Société française
      d'anesthésie et de réanimation (Sfar) in december 2015) permitted the achievement of
      adequatly serum and peritoneal concentrations in the medical and surgical management of
      peritonitis.

      The investigators will collected 3 pairs of serum and peritoneal fluid samples at 3 different
      times: peritoneal incision, arrival in ICU and 24 hours after admission in ICU in order to
      compare the concentrations and the minimal inhibitor concentration of bacteria.

      The hypothesis is that of a serum and peritoneal antibiotic under dosage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum and peritoneal beta lactams concentrations at 3 times</measure>
    <time_frame>3 times : Peritoneal incision, Admission in ICU and 24 hours after admission in ICU</time_frame>
    <description>Population : patients with surgical peritonitis. The concentrations are compared with the minimum inhibitory concentrations of bacteria to diagnose a sub therapeutic dosage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Factors associated with an antibiotic under-dosage</measure>
    <time_frame>Statistical analysis after 2 years of inclusion</time_frame>
    <description>effect of presence of septic shock on antibiotic concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors associated with an antibiotic under-dosage</measure>
    <time_frame>Statistical analysis after 2 years of inclusion</time_frame>
    <description>effect of volume ressucitation on antibiotic concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors associated with an antibiotic under-dosage</measure>
    <time_frame>Statistical analysis after 2 years of inclusion</time_frame>
    <description>effect of renal function on antibiotic concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the relationship between serum and peritoneal concentrations of beta-lactam</measure>
    <time_frame>Statistical analysis after 2 years of inclusion</time_frame>
    <description>Determination of the antibiotic diffusion coefficient through the peritoneal membrane : difference between serum concentration and peritoneal concentration of B lactam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity of included patients</measure>
    <time_frame>Reception on the 8th postoperative day</time_frame>
    <description>Morbidity is assessed by the presence or absence of second peritonitis surgery during hospitalization in ICU and at most 8 days (the mean of the peritonitis stays in the ICU of the investigators in 2016 is 8 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality of included patients</measure>
    <time_frame>Reception on the 8th postoperative day</time_frame>
    <description>The mortality is evaluated by the presence or absence of the death of the patient during the hospitalization in ICU and at most 8 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Peritonitis</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Peritonitis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient received for antibiotic treatment a B lactam according to French recommendation :
type of antibiotic : cefotaxime or ceftriaxone or piperacilline/tazobactam or imipenem
dose : cefotaxime 2g / cetriaxone 2g / piperacilline 4g / imipenem 1g</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dosage of serum and peritoneal of the B lactam used for antibiotic treatment</intervention_name>
    <description>Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM</description>
    <arm_group_label>Peritonitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimun age limits 18 years

          -  All sex

          -  Patients with peritonitis (community or nosocomial) regardless of pathology involved

          -  Patients treated in the Universty Hospital of Vandoeuvre les Nancy (abdominal surgery
             unit and surgical Intensive care unit JM Picard)

        Exclusion Criteria:

          -  Beta lactam allergy

          -  Pregnancy

          -  Age less than 18 years

          -  No respect of recommandations for antibiotics ( molecule and dosage)

          -  Person under legal protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel NOVY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU NANCY</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuel NOVY, MD</last_name>
    <phone>+33 3157437</phone>
    <email>e.novy@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>El Mehdi SIAGHY</last_name>
    <phone>+33 3155276</phone>
    <email>m.siaghy@chru-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel NOVY, MD</last_name>
      <phone>+33 383157437</phone>
      <email>e.novy@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2017</study_first_submitted>
  <study_first_submitted_qc>October 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic drug monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Lactams</mesh_term>
    <mesh_term>Cefotaxime</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

